Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting · NCT04054310 · Interventional (participants receive a specific treatment) · Lead sponsor: Perspectum
View the official record on ClinicalTrials.gov →Interventions studied
Liver Multi Scan
What this trial is about
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male and Female subjects aged between 18 and 75 years old
- Ability to understand and sign a written informed consent forms
- Patients scheduled to undergo a standard of care diagnostic liver biopsy as follows
- Percutaneous biopsy with a 16 gauged needle passed into the right lobe
- Trans-jugular biopsy with an 18 gauged needle passed into the right lobe
- Patients who are suspected of having NAFLD, who are being considered for treatment, and presenting with two or more of the following risk factors for NASH
- Elevated liver enzymes (ALT≥40)
- BMI≥25kG/m\^2
- Hypertension
- Type II diabetes
- Dyslipidameia
- Low High-density lipoprotein (HDL) (\<40mg/dl in men or \<50mg/dl in women)
- Hypertriglyceridemia (≥150mg/dl)
- Hypercholestrolemia (≥200mg/dl)
- Triglycerides (TG)/HDL\>5.0
Exclusion criteria
- Prior histopathological diagnosis of NASH
- Inability to undergo a liver biopsy
- Prior or planned liver transplantation
- Patient scheduled to undergo a laparoscopic or wedge liver biopsy or biopsy taken from the left lobe
- Participation in an investigational new drug (IND) trial in the 30 days before enrolment
- Other known causes of chronic liver disease based on clinical criteria at the study site such as the following:
- Alcoholic liver disease
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Autoimmune Hepatitis
- Wilson's disease, hemochromatosis, iron overload
- Alpha/1/Antitrypsin (A1AT) deficiency
- HCV, HBV
- History or diagnosis of cirrhosis and or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding
- Clinically relevant drug or alcohol abuse within 12 months of screening
- Any contradiction or significant limitation to MRI scanning
- Claustrophobia preventing MR imaging (requires 15-30 minutes in scanning)
- Pacemaker or another implanted device
- Metal in body (such as an aneurysm clip) that might produce artefacts on abdominal MRI or might be adversely impacted by a high magnetic field
- Inability to lie flat, remain still or briefly hold breath as necessary during MR imaging
- Medical condition likely to produce significant hypervolemia like congestive heart failure
- Severe obesity complicating positioning in MR scanner
- Weight reduction surgery within 3 years
- Concomitant medical illnesses per investigators discretion (such as HIV infection, recent major surgery, uncontrolled heart disease, concurrent infection or fever of unknown origin, illicit drug use, cancer
- Clinically significant medical or psychiatric condition considered a high risk participation in an investigational study
- Failure to give informed consent
Where it is running
7 locations listed across 6 US states.
- Arizona Liver Health - Chandler, Arizona, United States
- RUSH University Medical Center - Chicago, Illinois, United States
- Indiana University Health - Indianapolis, Indiana, United States
- Icahn School of Medicine at Mount Sinai - New York, New York, United States
- Liver Center of Texas - Dallas, Texas, United States
- University of Virginia - Charlottesville, Virginia, United States
- Virginia Common wealth University - Richmond, Virginia, United States